Table 1.
Cardiac-related clinical symptoms and measurements of adult patients with COVID-19-induced myocarditis (cohorts)
| Reference | Authors | Year | Number of cases | Country | Age (mean) | Male (%) | Physical exam | Myocarditis diagnostics | ECG | Echo | Imaging and Lab | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [53] | Daniels et al. | 2021 | 37 | US | NA | 73 | Chest pain, palpitations, dyspnea | CMR | NCM (non-compaction cardiomyopathy) | Abnormal, NCM | ↑T1, ↑T2, LGE, ↓LVE, ↑troponin | No deaths |
| [20] | Boehmer et al. | 2021 | 2116 | US | 54 | 60 | NA | ICD-10-CM | NA | NA | NA | NA |
| [54] | Huang et al. | 2020 | 26 | China | 38 | 38 | Precordial chest pain, palpitations, chest distress | CMR | NA | PE | ↑T1, ↑T2, LGE, ↑ECV | NA |
| [55] | Deng et al. | 2020 | 14 | China | 65 | 71 | Fever, cough, chest pain/tightness, shortness of breath | AHA guideline: triple elevation in troponin with either ECG changes or electrocardiographic changes | ST segment elevation/ST-T changes, tachycardia | Reduced LVEF (<50%), segmental wall motion abnormality, LV wall thickening, PE, TAPSE | ↑Troponin | 13 deaths |
| [70] | Laganà et al. | 2021 | 12 | Italy | 71 | 42 | NA | One criterion from ESC guidelines | Ischemic alteration, QTc prolongation | Diffuse LV hypokinesia | NA (no statistical significance) | 3 deaths |
| [71] | Buckley et al. | 2021 | 35820 | US | 48 | 44 | NA | ICD-10-CM | NA | NA | NA | NA |
| [72] | Martinez et al. | 2021 | 3 | US | 25 | NA | NA | CMR | Abnormal | New regional wall motion abnormality; preserved LVEF | NA | No deaths |
| [73] | Priyadarshni et al. | 2022 | 79 | US | NA | NA | NA | ICD-10-CM | NA | NA | NA | NA |